

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1194242
<b>Application Number:</b>	10598759
<b>Confirmation Number:</b>	9905
<b>Title of Invention:</b>	BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
<b>First Named Inventor:</b>	Mark James Bamford
<b>Customer Number:</b>	23347
<b>Filer:</b>	Bonnie L. Deppenbrock/Patricia Wilson
<b>Filer Authorized By:</b>	Bonnie L. Deppenbrock
<b>Attorney Docket Number:</b>	PB60780USw
<b>Receipt Date:</b>	11-SEP-2006
<b>Filing Date:</b>	
<b>Time Stamp:</b>	14:05:17
<b>Application Type:</b>	U.S. National Stage under 35 USC 371
<b>International Application Number:</b>	PCT/GB05/00939

### Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$ 900
RAM confirmation Number	1150
Deposit Account	071392
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17	

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	Transmittal letter	PB60780USw_371Transmittal.pdf	503571	no	3
Warnings:					
Information:					
2		PB60780USw_Prelim_Amended.pdf	119977	yes	24
	Multipart Description				
	Doc Desc		Start	End	
	Preliminary Amendment		1	2	
	Specification		3	3	
	Claims		4	22	
	Applicant Arguments/Remarks Made in an Amendment		23	23	
	Abstract		24	24	
Warnings:					
Information:					
3	Oath or Declaration filed	PB60780USw_Declaration.pdf	85082	no	3
Warnings:					
Information:					
4	Power of Attorney	PB60780USw_POA.pdf	47823	no	1
Warnings:					
Information:					
5	Assignee showing of ownership per 37 CFR 3.73(b).	373Statement_with_Assignment.pdf	829849	no	8
Warnings:					
Information:					
6	Documents submitted with 371 Applications	PB60780_IPR.pdf	229610	no	8
Warnings:					
Information:					

7	Documents submitted with 371 Applications	Pb60780USw_ISR_WrtnOpn.pdf	413441	no	14
<b>Warnings:</b>					
<b>Information:</b>					
8	Documents submitted with 371 Applications	PB60780USw_Request.pdf	100428	no	5
<b>Warnings:</b>					
<b>Information:</b>					
9	Foreign Reference	DE2207430.pdf	3514618	no	82
<b>Warnings:</b>					
<b>Information:</b>					
10	Foreign Reference	FR2171879.pdf	3164056	no	73
<b>Warnings:</b>					
<b>Information:</b>					
11	Foreign Reference	GB1268243.pdf	2945164	no	43
<b>Warnings:</b>					
<b>Information:</b>					
12	Foreign Reference	JP2001226269.pdf	7548352	no	88
<b>Warnings:</b>					
<b>Information:</b>					
13	Foreign Reference	WO0021951.pdf	4786549	no	102
<b>Warnings:</b>					
<b>Information:</b>					
14	Foreign Reference	WO0023437.pdf	10050685	no	260
<b>Warnings:</b>					
<b>Information:</b>					
15	Foreign Reference	WO0103680.pdf	2867912	no	62
<b>Warnings:</b>					
<b>Information:</b>					

16	Foreign Reference	wo0187834.pdf	11897176	no	285
<b>Warnings:</b>					
<b>Information:</b>					
17	Foreign Reference	WO0202530.pdf	9930185	no	217
<b>Warnings:</b>					
<b>Information:</b>					
18	Foreign Reference	WO0214513.pdf	14149733	no	292
<b>Warnings:</b>					
<b>Information:</b>					
19	Foreign Reference	WO0215934.pdf	9320797	no	190
<b>Warnings:</b>					
<b>Information:</b>					
20	Foreign Reference	wo0246186.pdf	8332941	no	190
<b>Warnings:</b>					
<b>Information:</b>					
21	Foreign Reference	wo0368752.pdf	2834619	no	56
<b>Warnings:</b>					
<b>Information:</b>					
22	Foreign Reference	wo02040471_R6A3.pdf	3846058	no	67
<b>Warnings:</b>					
<b>Information:</b>					
23	Foreign Reference	wo02059115.pdf	4044820	no	95
<b>Warnings:</b>					
<b>Information:</b>					
24	Foreign Reference	wo04056369.pdf	5136573	no	106
<b>Warnings:</b>					
<b>Information:</b>					

25	NPL Documents	BioMedChem2000.pdf	137532	no	3
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	BrJPharm1996.pdf	42322	no	2
<b>Warnings:</b>					
<b>Information:</b>					
27	NPL Documents	Giovannini1999.pdf	122404	no	9
<b>Warnings:</b>					
<b>Information:</b>					
28	NPL Documents	Leurs1998.pdf	1788385	no	7
<b>Warnings:</b>					
<b>Information:</b>					
29	NPL Documents	Lovenberg1999_Huvar.pdf	280857	no	7
<b>Warnings:</b>					
<b>Information:</b>					
30	NPL Documents	Onodera1998.pdf	1980803	no	16
<b>Warnings:</b>					
<b>Information:</b>					
31	NPL Documents	Schlicker1994.pdf	2418565	no	11
<b>Warnings:</b>					
<b>Information:</b>					
32	NPL Documents	Fukuij1994.pdf	1439007	no	8
<b>Warnings:</b>					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
<b>Information:</b>					
33	NPL Documents	Sarlo1966.pdf	817908	no	5

<b>Warnings:</b>					
<b>Information:</b>					
34	Information Disclosure Statement (IDS) Filed	IDS.pdf	443307	no	3
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
35	Fee Worksheet (PTO-875)	fee-info.pdf	8455	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			116179564		
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>  If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>  If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>					